Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study
Authors:
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (3) , 244.e1-244.e8
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
This publication has 43 references indexed in Scilit:
- Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction TherapiesTransplantation and Cellular Therapy, 2012
- Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and CyclophosphamideTransplantation and Cellular Therapy, 2011
- Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilizationBone Marrow Transplantation, 2010
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensBlood, 2009
- International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)Leukemia, 2009
- Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaBlood, 2009
- Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myelomaBone Marrow Transplantation, 2008
- Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patientsLeukemia, 2007
- Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myelomaBone Marrow Transplantation, 2003
- A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patientsBone Marrow Transplantation, 2001